Melatonin MT1 receptor-induced transcriptional up-regulation of p27Kip1 in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): Potential implications on prostate cancer chemoprevention and therapy

Journal of Pineal Research

Volumn 54, Issue 1, 2013, Pages 69-79

  Shiu, Stephen Y W ^a   Leung, Wai Y ^b   Tam, Chun W ^a,c   Liu, Vincent W S ^a   Yao, Kwok Ming ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c OPEN UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Melatonin; MT1 receptor; Nuclear factor kappa B; P27Kip1; Prostate

Indexed keywords

2 IODOMELATONIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; MELATONIN 1 RECEPTOR; PROTEIN KINASE C;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASE PAIRING; BINDING SITE; CELL PROLIFERATION; CELL STRAIN LNCAP; CHEMOPROPHYLAXIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; GENE MAPPING; HUMAN; HUMAN CELL; MALE; PROMOTER REGION; PROSTATE CANCER; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION; UPREGULATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MT1 RECEPTOR; P27KIP1; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

MELATONIN; MT1 RECEPTOR; NUCLEAR FACTOR KAPPA B; P27KIP1; PROSTATE;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; HUMANS; MALE; MELATONIN; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTOR, MELATONIN, MT1; UP-REGULATION;

EID: 84872684040     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2012.01026.x     Document Type: Article

References (41)

1. FERLAY J, SHIN HR, BRAY F et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France, 2010. Available from: http://globocan.iarc. fr.
2. REITER RJ, TAN DX, KORKMAZ A et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit Rev Oncog 2007; 13:303-328.
3. SHIU SYW. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res 2007; 43:1-9.
4. JOO SS, YOO YM. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer. J Pineal Res 2009; 47:8-14.
5. PARK JW, HWANG MS, SUH SI et al. Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J Pineal Res 2009; 46:415-421.
6. JUNG-HYNES B, REITER RJ, AHMAD N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res 2010; 48:9-19.
7. JUNG-HYNES B, HUANG W, REITER RJ et al. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49:60-68.
8. JUNG-HYNES B, SCHMIT TL, REAGAN-SHAW SR et al. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011; 50:140-149.
9. CHO SY, LEE HJ, JEONG SJ et al. Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1a inactivation in hypoxic PC-3 prostate cancer cells. J Pineal Res 2011; 51:87-93.
10. XI SC, TAM PC, BROWN GM et al. Potential involvement of mt1 receptor and attenuated sex-steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res 2000; 29:172-183.
11. XI SC, SIU SWF, FONG SW et al. Inhibition of androgensensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 2001; 46:52-61.
12. SIU SWF, LAU KW, TAM PC et al. Melatonin and prostate cancer cell proliferation: Interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002; 52:106-122,
13. [Erratum, Prostate 2002; 52:252.].
14. TAM CW, MO CW, YAO KM et al. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res 2007; 42:191-202.
15. TAM CW, CHAN KW, LIU VW et al. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res 2008; 45:403-412.
16. SHIU SYW, PANG B, TAM CW et al. Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Gas and Gaq proteins. J Pineal Res 2010; 49:301-311.
17. TAM CW, SHIU SYW. Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. J Pineal Res 2011; 51:297-312.
18. SHIU SYW, LAW IC, LAU KW et al. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res 2003; 35:177-182.
19. FERNÁNDEZ PL, ARCE Y, FARRÉ X et al. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 1999; 187:563-566.
20. KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001; 27:222-224.
21. MAJUMDER PK, GRISANZIO C, O'CONNELL F et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008; 14:146-155.
22. MINAMI S, OHTANI-FUJITA N, IGATA E et al. Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett 1997; 411:1-6.
23. SWEENEY C, LI L, SHANMUGAM R et al. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004; 10:5501-5507.
24. PALAYOOR ST, YOUMELL MY, CALDERWOOD SK et al. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18:7389-7394.
25. PRASAD RC, WANG XL, LAW BK et al. Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-kappaB. Cancer Lett 2009; 275:139-149.
26. ZHANG L, ALTUWAIJRI S, DENG F et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009; 175:489-499.
27. GASPARIAN AV, YAO YJ, KOWALCZYK D et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002; 115:141-151.
28. SUH J, PAYVANDI F, EDELSTEIN LC et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002; 52:183-200.
29. CHUANG JI, MOHAN N, MELTZ ML et al. Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen. Cell Biol Int 1996; 20:687-692.
30. GILAD E, WONG HR, ZINGARELLI B et al. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J 1998; 12:685-693.
31. GRIVENNIKOV SI, GRETEN FR, KARIN M. Immunity, inflammation, and cancer. Cell 2010; 140:883-899.
32. KARIN M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-436.
33. DE MARZO AM, PLATZ EA, SUTCLIFFE S et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256-269.
34. KARIN M, GRETEN FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-759.
35. SUH J, RABSON AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004; 91:100-117.
36. SAVLI H, SZENDRÖI A, ROMICS I et al. Gene network and canonical pathway analysis in prostate cancer: a microarray study. Exp Mol Med 2008; 40:176-185.
37. OKAZAKI IM, KOTANI A, HONJO T. Role of AID in tumorigenesis. Adv Immunol 2007; 94:245-273.
38. COLOTTA F, ALLAVENA P, SICA A et al. Cancer-related inflammation, the seventh hall mark of cancer: links to genetic instability. Carcinogenesis 2009; 30:1073-1081.
39. ATTARD G, COOPER CS, DE BONO JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16:458-462.
40. JIN RJ, LHO Y, CONNELLY L et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68:6762-6769.
41. NAKANISHI C, TOI M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-309.